PCSK9 Inhibitor Use in the Real World: Data From the National Patient‐Centered Research Network

BACKGROUND: PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors effectively lower LDL (low‐density lipoprotein) cholesterol and have been shown to reduce cardiovascular outcomes in high‐risk patients. We used real‐world electronic health record data to characterize use of PCSK9 inhibito...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Am Heart Assoc
Hlavní autoři: Chamberlain, Alanna M., Gong, Yan, Shaw, Kathryn McAuliffe, Bian, Jiang, Song, Wen‐Liang, Linton, MacRae F., Fonseca, Vivian, Price‐Haywood, Eboni, Guhl, Emily, King, Jordan B., Shah, Rashmee U., Puro, Jon, Shenkman, Elizabeth, Pawloski, Pamala A., Margolis, Karen L., Hernandez, Adrian F., Cooper‐DeHoff, Rhonda M.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512121/
https://ncbi.nlm.nih.gov/pubmed/31020929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.118.011246
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky